The effects of 4-weeks treatment with granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with peripheral artery disease were investigated in a phase 2 double-blind, placebo-controlled study. At 3 months, no differences were observed in peak treadmill walking time between patients treated with GM-CSF (n = 80) and those treated with placebo (n = 79). Patients treated with GM-CSF treatment did, however, have improved distance scores in the walking impairment questionnaire and physical function subcores in the SF-36 questionnaire.
References
Poole, J. et al. Effect of progenitor cell mobilization with granulocyte-macrophage colony-stimulating factor in patients with peripheral artery disease. A randomized clinical trial. JAMA 10.1001/jama.2013.282540
Rights and permissions
About this article
Cite this article
Treatment of peripheral artery disease with GM-CSF. Nat Rev Cardiol 11, 5 (2014). https://doi.org/10.1038/nrcardio.2013.192
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2013.192